SemBioSys submits IND for safflower-produced insulin to U.S. FDA (CNW Group via Yahoo! Finance)
SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has submitted an Investigational New Drug application for safflower-produced recombinant human insulin to the United States Food and Drug Administration .

Vanda Pharmaceuticals Announces Receipt Of Not Approvable Letter From FDA For Iloperidone (Medical News Today)
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced the receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application for iloperidone, an investigational atypical antipsychotic that was reviewed for the treatment of schizophrenia.